The FDA's assessment of the bread recall has designated it as a Class II risk, which means the product "may cause temporary ...

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

Confused about hair transplant vs hair restoration? Learn the key differences, benefits, and which option might be right for ...

Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.